Wong Weng Kee, Ryeznik Yevgen, Sverdlov Oleksandr, Chen Ping-Yang, Fang Xinying, Chen Ray-Bing, Zhou Shouhao, Lee J Jack
Department of Biostatistics, University of California, Los Angeles, CA, USA.
Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Clin Trials. 2025 Aug;22(4):422-429. doi: 10.1177/17407745251346396. Epub 2025 Jul 12.
Metaheuristics are commonly used in computer science and engineering to solve optimization problems, but their potential applications in clinical trial design have remained largely unexplored. This article provides a brief overview of metaheuristics and reviews their limited use in clinical trial settings. We focus on nature-inspired metaheuristics and apply one of its exemplary algorithms, the particle swarm optimization (PSO) algorithm, to find phase I/II designs that jointly consider toxicity and efficacy. As a specific application, we demonstrate the utility of PSO in designing optimal dose-finding studies to estimate the optimal biological dose (OBD) for a continuation-ratio model with four parameters under multiple constraints. Our design improves existing designs by protecting patients from receiving doses higher than the unknown maximum tolerated dose and ensuring that the OBD is estimated with high accuracy. In addition, we show the effectiveness of metaheuristics in addressing more computationally challenging design problems by extending Simon's phase II designs to more than two stages and finding more flexible Bayesian optimal phase II designs with enhanced power.
元启发式算法在计算机科学和工程领域常用于解决优化问题,但其在临床试验设计中的潜在应用在很大程度上仍未得到探索。本文简要概述了元启发式算法,并回顾了它们在临床试验环境中的有限应用。我们聚焦于受自然启发的元启发式算法,并应用其一种典型算法——粒子群优化(PSO)算法,来寻找同时考虑毒性和疗效的I/II期设计。作为一个具体应用,我们展示了PSO在设计最优剂量探索研究中的效用,以估计多约束条件下具有四个参数的连续比例模型的最优生物剂量(OBD)。我们的设计通过保护患者不接受高于未知最大耐受剂量的剂量,并确保高精度估计OBD,改进了现有设计。此外,我们通过将西蒙的II期设计扩展到两个以上阶段,并找到具有更高功效的更灵活的贝叶斯最优II期设计,展示了元启发式算法在解决计算上更具挑战性的设计问题方面 的有效性。